Exam C Study Guide Flashcards

1
Q

Goals of Transfusion Therapy?

A

to increase tissue oxygenation and/or restore hemostasis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Four Major Categories of Blood Products?

A

-Cellular components
-Plasma components
-Hematopoietic progenitor cell (HPC)
-Plasma fractionation products

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the different cellular components?

A

-whole blood
-red cells
-granulocytes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the different plasma components?

A

platelet products, cryoprecipitate, fresh frozen plasma, other transfusable plasma components

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the Hematopoietic progenitor cell (HPC) products?

A

bone marrow, peripheral blood stem cell and cord blood cell preparations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are the plasma fractionation products?

A

albumin, various immune globulins, coagulation factor concentrates

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Acid-citrate-dextrose:

-good for ____ days
-pH?

A

-21
-lowest pH of any blood preservatives

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are the different Red Blood Cell preservatives?

A

-ACD
-CPD
-CPDA-1
-CP2D-AS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Citrate-phosphate-dextrose (CPD):

-good for ____ days
-pH?

A

-21 days
-Decreases red blood cell pH; however, not as much as ACD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Citrate-phosphate-dextrose-adenine (c. CPDA-1):

-good for _____days

A

35

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What does Citrate-phosphate-dextrose-adenine (CPDA-1) do?

A

-Adenine increases ADP levels therefore causing ATP formation
-Decreased 2,3 DPG by day 35

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Citrate-phosphate-dextrose (CP2D-AS):

-good for _____ days

A

42

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the advantage of Citrate-phosphate-dextrose (CP2D-AS)?

A

2,3 DPG and ATP values are improved over CPDA-1; however, by the 42nd day the 2,3 DPG and ATP levels are significantly decreased

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the additive solutions used for RBC preservation?

A

AS-1, AS-3, AS-5

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What dos AS-1, AS-3,
and AS-5 all have?

A

All have saline, adenine and glucose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Additive solutions:

___ and ____ have mannitol to protect against storage lesions.

A

AS-1, AS-5

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Additive solutions:

____ has citrate and phosphate to protect from storage lesions.

A

AS-3

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

AS-____ is approved in Europe, but not in the US

A

7

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

The infusion of all blood components should occur in less than ____ hours.

A

4

-The infusion rate may be adjusted to allow for individual patient circumstances but should fall within the 4-hour limit.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What should be documented as part of the order to transfuse?

A

infusion rate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

The 4-hour limit does not necessarily apply to infusion of __________ products

A

fractionation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

The basic infusion set incorporates flexible plastic tubing and a standard inline blood filter with a pore size of ______ microns.

A

170–260

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

_____________ filters may be used for red blood cell transfusions.

A

Microaggregate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Leukocyte reduction filters are used to reduce the number of white blood cells in red blood cell or platelet components to less than _____ white blood cells per unit.

A

5 × 10^6

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Are filters used for red blood cell components interchangeable with the filters designed for platelet components?

A

No

-Using a needle with too small a bore diameter may cause hemolysis when transfusing red blood cells. As with other transfusion parameters, needle size may vary with patient conditions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Why should the infusion rate be slowed when using smaller needles when transfusing RBCs?

A

to prevent hemolysis

-Needles with a large-bore diameter should be used when rapidly transfusing red blood cells.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

-Rapid infusers resemble pressure cuffs that surround the entire bag of blood.
-Rapid infusers should not be inflated to _____mm Hg or above because this level of pressure may cause the bag to rupture.

A

300

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Massive rapid infusion or infusion into a central venous catheter carries a higher risk of __________.

A

hypothermia

Blood warmers can be used to prevent hypothermia but should be maintained and monitored so the blood never reaches a temperature that could cause hemolysis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

__________ pumps can be used to regulate the blood flow into the patient.
-These are often used in neonates where small shifts in volume may drastically affect the infant

A

Mechanical

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

When would mechanical pumps be used in adults?

A

when rate control is indicated.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

True or false:

Normal saline, 0.9% sodium chloride (USP), may be added to most blood components.

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Generally, medications and other intravenous solutions should not be added to blood components as they may cause…

A

clotting or hemolysis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Some examples of substances that have regulatory approval to safely add to red blood cell units include…

A

ABO-compatible plasma, 5% albumin, and Plasma-Lyte®.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Ringer’s lactate solution should not be added to blood components because the high _______ content inactivates the anticoagulant, causing clots to form.

A

calcium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

What are the uses of whole blood?

A

-Exchange transfusions
-Acute massive blood loss

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

True or false:

Fresh whole blood may be used in specific circumstances but for the most part it has been replaced by specific component therapy

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

If whole blood is used, it should be ____ identical and should be crossmatched.

A

ABO

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

Each unit of whole blood should increase the patient’s hematocrit by ___% and hemoglobin by ___%

A

3, 1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

Storage time for Whole blood:

-CPD up to ___ days
-CPDA-1 up to ___ days
-CPD-AS up to ____ days

A

21
35
42-45

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

What are some of the uses of Packed Red Blood Cells?

A

-Anemia
-Most blood replacements during surgery
-Pre-operative transfusions
-In severe, acute blood loss it, along with other components and fluids can correct the situation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

What is the storage time for PRBCs compared to whole blood

A

the same

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

Patients with a hemoglobin concentrate above ___/dL (100 g/L) rarely need a blood transfusion.

A

10

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

Patients with a hemoglobin below ___ g/dL (70 g/L)… many patients experience symptoms of poor oxygenation and benefit from red blood cell transfusions.

A

7

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

Between ____ and ___ g/dL (70 and 100 g/L), the patient’s clinical presentation and the particular problem being treated exert more influence on the decision to transfuse.

A

7, 10

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

Stored whole blood may be used in preoperative autologous donation (PAD) programs, when a patient donates one or more units of blood _____ weeks before a scheduled surgery.

A

1-3

In PAD, collected units are often held as whole blood to eliminate the costs involved in component preparation and storage.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

Directed Donation:

If the donation is from a first-degree family member, this unit must be _______ prior to infusion in order to prevent transfusion-associated graft versus host disease (TA-GVHD).

A

irradiated

-Units are screened for infectious diseases in the same manner as community donors.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

Directed Donations:

What is done with plasma portions of the units?

A

Directed units are processed into packed red blood cell units. Plasma portions of these units are usually placed in the main donor supply and not designated for the recipient of the directed donation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

Ture or false:

If the red blood cell unit is not transfused to the intended recipient it may cross over into the main donor supply.

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

Granulocyte Transfusion is used primarily to treat?

A

neutropenic patients who have bacterial and/or fungal sepsis that has been shown to be resistant to antimicrobial interim therapy. Thus, granulocyte therapy is not generally a first-line therapy for these patients.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

Granulocyte Transfusion is given as interim therapy for what patients?

A

for patients who are expected to recover neutrophil production, as well as those with congenital abnormalities in neutrophil function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

Granulocytes are prepared from either apheresis technique or from fresh whole blood. They are stored at room temperature and expire _________ after preparation

A

24 hours

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

Granulocyte units should be transfused as soon as possible, and must be transfused within ___ hours of collection, to obtain the most viable cell dose.

A

24

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q

Granulocyte units should always be irradiated to prevent ______ but should not be infused with microaggregate or leukoreduction filters.

A

TA-GVHD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
54
Q

The donor and recipient should be both ___ and ______________ (HLA) compatible.

A

Rh and human leukocyte antigen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
55
Q

A crossmatch should be performed if more than ___ mL of red blood cells are present in the granulocyte unit.

A

2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
56
Q

Leukocyte reduction filters are available that can be used with…

A

whole blood, red blood cell or platelet units.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
57
Q

Purpose of leukoreduction?

A

Helps to prevent the formation of antibodies to HLA antigens because white blood cells carry HLA antigens.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
58
Q

Leukoreduction can be done by…

A

centrifugation, filtering upon unit preparation, washing the product or filtering at bedside.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
59
Q

Who should receive leukoreduced cellular blood products?

A

Patients who would be most adversely affected by alloimmunization to HLA antigens (duh)

-Other patients that benefit from leukoreduction are patients with febrile, nonhemolytic transfusion reactions.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
60
Q

Leukoreduction decreases the viral load in the product and therefore can reduce the incidence of transfusion-related transmission of viruses known to reside on white blood cells (such as…

A

human T-cell lymphotropic virus [HTLV-1] and Epstein-Barr virus [EBV])

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
61
Q

Leukoreduction can also prevent ________ to platelet transfusions

A

rectroriness

-Please note that single-donor platelets can be collected by an apheresis machine in a manner that renders the product leukodepleted during the collection process

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
62
Q

What is irradiation used for?

A

To prevent TA-GVHD (transfusion-associated graft-versus-host disease).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
63
Q

TA-GVHD occurs when viable transfused lymphocytes…

A

replicate in the recipient, recognize them as foreign, and mount a destructive immune response against the recipient’s body.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
64
Q

What is the risk of TA-GVHD (transfusion-associated graft-versus-host disease)?

A

a pancytopenia within days of the transfusion and is almost uniformly fatal.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
65
Q

This disrupts the DNA in the white blood cell nuclei, which destroys the white blood cell’s ability to replicate.

A

Gamma irradiation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
66
Q

To prevent TA-GVHD the blood component should receive a radiation dose of _____ Gy (2500 cGY) delivered to the midplane and ___ Gy (1500 cGy) to all parts of the bag.

A

25, 15

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
67
Q

Since immunocompromised patients are most susceptible to TA-GVHD, they commonly receive _________ red blood cell and platelet units.

A

irradiated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
68
Q

Products that are from a first-degree relative of the recipient must be __________, as the recipient would be at a high risk for TA-GVHD

A

irradiated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
69
Q

CMV infection is often asymptomatic in a person with a robust immune system.
In immune suppressed individuals, CMV infection can cause…

A

debilitating effects and even death.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
70
Q

Patient populations where transfusion-transmitted CMV infection can cause significant morbidity and mortality include:

A

-Low birth weight infants (<1500g)
-CMV seronegative HPC transplant recipients or potential recipients
-CMV seronegative antepartum women
-Fetuses receiving intrauterine transfusion
-HIV-infected patients and children born to HIV-positive mothers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
71
Q

What are the two methods to decrease the risk of transfusion-associated CMV transmission?

A

-Leukoreduction
-Testing blood donors for antibodies to CMV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
72
Q

How does leukoreduction prevent CMV?

A

CMV infects white blood cells; therefore, leukoreduction can reduce the viral load in blood components

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
73
Q

In order to reduce CMV transmission and HLA alloimmunization, some countries have converted their blood supply to __________.

A

prestorage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
74
Q

What is the incidence of CMV infection in the general population?

A

varies and can be quite high.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
75
Q

Will leukoreduction or CMV seronegativity confer complete protection from CMV?

A

-neither confer complete protection from transition.

-The combo of both offers the most protection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
76
Q

Washing of red blood cell and platelet units is indicated in only a few clinical situations.
The procedure uses centrifugation most often in an _____ system.

A

open

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
77
Q

Washed red blood cell units expire in _____ hours from the time of washing, platelets in ___ hours.

A

24, 4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
78
Q

***Washing of red blood cell units eliminates approximately ____% of the white blood cells, about ____% of red blood cell mass, and virtually ____% of the plasma.

A

85, 15, 99

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
79
Q

True or false:

Washed red blood cell and platelet components can be transfused to IgA-deficient patients who have antibodies to IgA.

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
80
Q

_________ may be indicated in patients who have severe allergic reactions to blood products.

A

Washing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
81
Q

Washing should not be used as a means to reduce __________.

A

white blood cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
82
Q

Blood from donors with rare red blood cell phenotypes may be stored frozen for up to ____ years and used for autologous or allogeneic transfusion.

A

10

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
83
Q

Freezing:

Each unit is phenotyped extensively prior to freezing using a cryoprotective agent, such as 20 or 40% glycerol. When the unit is to be transfused the cryoprotective agent must be washed; this process is called _____________.

A

deglycerolization

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
84
Q

The deglycing procedure is as follows:
a. ____% sodium chloride solution
b. _____% sodium chloride solution with 0.2 gm% glucose solution

A

12%, 0.9%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
85
Q

The expiration date of the deglycerolized red blood cell components is ______hours for open systems or ____weeks for closed systems

A

24, 2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
86
Q

True or false:

Cryopreservation of platelets is widely available.

A

False. Not widely available.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
87
Q

_______ is the most common cryopreservative used for frozen platelet storage.

A

DMSO

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
88
Q

Frozen platelet products can be stored for ___ years.

A

2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
89
Q

What are three types of plasma-derived products commonly used?

A

Fresh frozen plasma (FFP), platelet products, and cryoprecipitate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
90
Q

FFP normally comes from whole blood donations.
-It must be removed and frozen within ____ hours.

A

8

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
91
Q

Fresh Frozen Plasma is primarily used to…

A

to replace dysfunctional or deficient coagulation proteins. Coagulation factor deficiencies are usually caused by congenital diseases.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
92
Q

Fresh Frozen Plasma uses:

Multiple coagulation deficiencies are often present in patients with _______ damage or failure.

A

liver

-Vitamin K antagonists or deficiencies affect multiple coagulation factors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
93
Q

What is the storage for FFP when frozen?

A

-18oC or colder for 1 year

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
94
Q

What is the storage for FFP when thawed?

A

1-6oC for 4 hours or 5 days, but 5 day storage loses some of the important coagulation factors.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
95
Q

1 unit of FFP should increase the coagulation factors by about _____%.

A

25-30

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
96
Q

FFP should not be used to dilute red blood cell units for faster infusion. ____________ can be used and will not expose the patient to another donor.

A

Crystalloids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
97
Q

Specific coagulation factor concentrates have largely replaced FFP as the treatment of choice for people with congenital factor abnormalities. FFP is usually only used if…

A

no factor concentrate is available.The decision to treat patients with FFP should not be based solely on laboratory values but should take into consideration the patient’s underlying disease and clinical status.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
98
Q

Platelet components are prepared from a single donor or random donor. The single donor is typically an apheresis procedure in which one bag is equivelant to ____ random donor platelets. The random donor platelet is obtained from a whole blood donation.

A

6-8

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
99
Q

Platelets are viable for up to ___ days, but must be stored at room temp and continuously shaken and if the system is opened, they will expire in ___ hours upon opening.

A

5, 4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
100
Q

Platelet uses?

A

-Indicated in a variety of clinical situations where decreased platelet production, increased platelet destruction, or platelet dysfunction may lead to bleeding.
-Certain thrombocytopenic patients may benefit from prophylactic platelet transfusion to reduce bleeding risk.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
101
Q

A platelet count of less than _______________ is often used as a trigger to initiate prophylactic platelet transfusions to prevent intracranial hemorrhage.

A

10 × 10^3/µL (10 × 109/L)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
102
Q

Common patient groups with low platelet counts that are treated prophlactically include:

A

-Premature neonates
-Cancer patients receiving chemotherapy and transplant patients
-Transplant patients of both solid organ and HPC.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
103
Q

1 unit of platelets should increase the platelet count by…

A

5,000-10,000

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
104
Q

Many donor centers primarily collect apheresis platelet products, which are also called single-donor platelets. For adults, the usual dose per transfusion is ___ apheresis platelet or ____ whole blood–derived platelets. Typical dosage of whole blood–derived platelets can vary among facilities from 4 to 10 units per dose. Apheresis platelets where the donor and recipient are matched for certain antigens may be transfused when a recipient becomes refractory to platelet transfusions.

A

1, 6

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
105
Q

Cryoprecipitate is manufactured from what blood component?

A

FFP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
106
Q

The major use of cryoprecipitate is as a source of ___________.

A

fibrinogen

-but can also be used to treat congenital deficiencies or dysfunctions of fibrinogen.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
106
Q

What does Cryoprecipitate contain?

A

contains factor VIII, fibrinogen, von Willebrand factor (vWF), Factor XIII, and fibronectin.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
106
Q

What is storage for cryoprecipitate?

A

-18oC for one year from draw date
- room temperature for 4 hours after thawing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
107
Q

Cryoprecipitate:

One bag should increase Factor VIII by ____ units and Factor 1 by ____mg/dL

A

80

5

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
108
Q

What may eventually replace the use of cryoprecipitate as fibrinogen replacement?

A

Human fibrinogen (RiastapTM) was approved by the U.S. Food and Drug Administration (FDA) in 2009 to treat patients with a congenital fibrinogen deficiency. A recombinant human fibrinogen product is available in Europe and may eventually replace the use of cryoprecipitate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
109
Q

Plasma Fractionation Products: The FDA and the __________ Association provide oversight and accreditation of plasma fractionation facilities in the United States.

A

Plasma Protein Therapeutics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
110
Q

Who distributes plasma fractionation products?

A

by the transfusion service or by the pharmacy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
111
Q

What are Coagulation Factor Concentrates used for?

A

to prevent or to treat bleeding episodes in patients with coagulation deficiencies
-targeted therapy with the appropriate factor concentrate.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
112
Q

What are the benefits of Factor concentrates over broad-spectrum treatment with FFP transfusion?

A

are easier to transfuse and safer for the patient

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
113
Q

Factor concentrates have a smaller volume and have less risk of disease transmission because of what step?

A

viral inactivation steps used in the manufacturing process.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
114
Q

Several factor concentrates are now made in a recombinant form and contain no human plasma-derived products, reducing the risk of infectious disease transmission theoretically to _____.

A

zero

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
115
Q

What are the most commonly used factor concentrates?

A

-Factor VIII
-Factor IX
-Factor VIIa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
116
Q

Other plasma-derived protein concentrates include…

A

antithrombin, protein C, and C1-esterase inhibitor.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
117
Q

Factor VIII is for the treatment of…

A

Hemophilia A, von Willebrand’s disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
118
Q

Factor IX is for the treatment of…

A

Hemophilia B

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
119
Q

Factor VIIa is for the treatment of…

A

either hereditary or acquired Factor VII deficiency.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
120
Q

The protein that is present in the largest amount in human plasma.

A

Albumin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
121
Q

-Contributes to fluid balance both within the blood vessels and throughout the body.
-Most commonly used as a volume replacement in trauma, shock, burns, and therapeutic plasma exchange.

A

Albumin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
122
Q

Common indications for the administration of RhIg include:

A

-Rh(D)-negative mothers in the 28th week of pregnancy
-Following delivery of an Rh(D)-positive infant.
-Pregnant Rh(D)-negative women who are at increased risk for a feto–maternal hemorrhage in the perinatal period
-Rh(D)-positive platelets to an Rh(D)-negative woman of childbearing age

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
123
Q

Administered to prevent immunization to the D antigen.

A

Rh Immune Globulin (RhIg)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
124
Q

RhIg is often administered intramuscularly when given in what period?

A

in the perinatal or postnatal period.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
125
Q

The route chosen for post-transfusion RhIg administration is often dependent on…

A

on the dose of RhIg that will be given.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
126
Q

______ may be used in some cases as an alternative to intravenous immunoglobulin (IVIG) for the treatment of immune thrombocytopenia (ITP).

A

RhIg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
127
Q

Intravenous Immune Globulin (IVIG)
-Used to treat a variety of disorders, including:

A

a. Primary immune deficiencies
b. Acquired immune deficiencies
c. Autoimmune disorders
d. Infectious diseases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
128
Q

Defined as replacement of a patient’s total blood volume with donor components within 24 hours

A

Massive Transfusion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
129
Q

Most facilities generally define massive transfusion as more than ___ red blood cell units transfused in 24 hours or less.

A

10

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
130
Q

Adverse Transfusion Reactions:

Usually not used to describe transfusion-transmitted bacterial, viral, prion, or parasitic infections.

Ture or false?

A

True

-All other unintended adverse events are normally described under the umbrella term of transfusion reactions.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
131
Q

Reactions are commonly classed as acute if they occur within ___ hours of transfusion.

A

24

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
132
Q

May present anywhere from one day to two or more weeks after transfusion.

A

Delayed Transfusion Reactions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
133
Q

Transfusion-Reaction Surveillance:

What are the two oldest and most well-established surveillance networks?

A
  • Serious Hazards of Transfusion (SHOT) – a voluntary reporting scheme in the United Kingdom.
  • Haemovigilance Network of the Agence française de sécurité des produits de santé (AFSSAPS) – a mandatory reporting scheme in France.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
134
Q

A biovigilance system was first proposed in the United States in 2006, a collaborative effort involving both public and private organizations. The national ___________ program, which is one of the four components that make up the complete system, was launched in 2010.

A

hemovigilance

  • In the United States, the FDA has a guidance document that outlines steps for notifying the agency of any fatalities related to blood collection or transfusion
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
135
Q

Do adverse transfusion reactions have to be rported?

A

No. , but any transfusion-associated fatalities area required to be reported to the Centre for Biologics Evaluation and Research (CBER) as soon as possible, with a full written report required within 7 days.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
136
Q
  • One of the best known and most completely characterized adverse events in transfusion medicine.
  • Most commonly associated with patient antibodies that are directed against antigens present on the transfused red blood cells.
A

Immune-Mediated Hemolytic Transfusion Reaction

  • Pretransfusion testing and patient identification procedures have been designed primarily to prevent this reaction.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
137
Q

Immune-Mediated Hemolytic Transfusion Reaction can be divided into what two groups?

A

 Acute hemolytic reactions
 Delayed hemolytic reactions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
138
Q

The most serious acute hemolytic reactions occur as a result of patients receiving ____-incompatible red blood cells, either through misidentification of the patient, the specimen, or the blood component, or through errors in pretransfusion testing

A

ABO

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
139
Q

Delayed hemolytic reactions are most often due to the presence of patient antibodies to…

A

non-ABO red blood cell antigens.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
140
Q

Symptoms of acute hemolytic reactions

A

Infusion site pain, hypotension, wheezing, chest pain, flushing, and gastrointestinal symptoms.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
141
Q

Acute hemolytic reactions are Characterized by blank abnormalities.

A

is also characterized by associated coagulation abnormalities.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
142
Q

What type of damage is associated with acute hemolytic reactions

A

Renal damage is a significant risk for patients experiencing an acute hemolytic reaction.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
143
Q

Laboratory diagnosis of acute hemolytic anemia

The laboratory investigation is key to

The DAT will be what

what should be ruled out

A

-The laboratory investigation is key to correctly diagnosing an acute hemolytic transfusion reaction, particularly a clerical check to identify any errors in patient or blood component identification.
-In most cases, the post-transfusion direct antiglobulin test (DAT) will be positive; however, a negative DAT should not rule out the diagnosis of having this type of reaction.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
144
Q

Acute hemolytic anemia transfusion reactions

The most important first step when an adverse reaction is suspected is to

A

stop the transfusion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
145
Q

Acute Hemolytic Transfusion Reaction

Treatment depends on what

what is used to increase urine output and improve blood flow

A
  • Treatment depends on the amount of incompatible blood transfused and the severity of the patient’s symptoms.
  • Lasix may be used to increase urine output and improve blood flow to the kidneys.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
146
Q

Acute Hemolytic Transfusion Reaction

What may be administered?

The most common cause of Acute hemolytic anemias

A

i. Platelets, plasma, and/or cryoprecipitate may be administered.

xii. The most common cause is a patient receiving the incorrect blood component.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
147
Q

The most important tool in preventing an acute hemolytic reaction is

A

i. The most important tool in preventing an acute hemolytic reaction is strict adherence to policies and procedures.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
148
Q

Acute hemolytic transfusion reactions

patients present with or without what

what is present in the urine

A
  • Fever with or without chills
  • Hemoglobinuria
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
149
Q

patients with Acute hemolytic anemia will often present with

what condition correlates with acute hemolytic anemia

A

Dyspnea(SOB) or hypotension that can progress to shock

DIC or disseminated intravascular shock

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
150
Q

Delayed hemolytic transfusion reactions

Events are often what

known to occur with much greater what

A

i. Events are often unrecognized and frequently go unreported.
ii. Known to occur with much greater frequency than acute hemolytic reactions.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
151
Q

Delayed Hemolytic Transfusion Reaction

Begin the same way as acute hemolytic reactions, but blank is not initiated, and reactions tend to be blank.

A

iii. Begin much the same way as acute hemolytic reactions; however, complement activation is not initiated or is incomplete.
iv. Reaction tends to be less severe than acute hemolytic reactions.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
152
Q

Delayed Hemoloytic Transfusion Reaction

Symptoms

reactions can progress to

A

i. Symptoms include fever and anemia days to weeks after transfusion along with signs of extravascular hemolysis, including jaundice, leukocytosis, and hemoglobinuria.
ii. Reaction in some patients can progress to hyperhemolysis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
153
Q

b. Delayed Hemolytic Transfusion Reaction

Lab follow-up is key to

Treatment generally consists of

A

vi. Laboratory follow-up is key to diagnosing.
vii. Treatment generally consists of observation and supportive care.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
154
Q

b. Delayed Hemoloytic Transfusion Reaction

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
155
Q

b. Delayed Hemolytic Transfusion Reaction

If the resulting anemia necessitates additional transfusions, then

A

viii. If the resulting anemia necessitates additional transfusions, red blood cells negative for the antigen(s) against which the patient’s antibody(ies) is directed must be selected in order to prevent further hemolysis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
156
Q

b. Delayed Hemolytic Transfusion Reaction

For patients who remain unresponsive blank can be done

Errors that cause the reaction can be mitigated by what

A

x. For patients who remain unresponsive, a splenectomy may be indicated.
xi. Errors that cause this reaction can be mitigated by strict adherence to all policies and procedures around pretransfusion testing and blood component administration. Use of technology and automation can also reduce the risk of human error.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
157
Q

b. Delayed Hemolytic Transfusion Reaction

Complete patient history can help what

A

xii. A complete patient history can often help identify patients that are at an increased risk for delayed hemolytic transfusion reactions.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
158
Q

b. Delayed Hemolytic Transfusion Reaction

Testing for recently transfused or pregnant patients must be performed with samples drawn no more then.

A

xiii. Testing for recently transfused or pregnant patients must be performed with samples drawn no more than 3 days before planned transfusion.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
159
Q

Febrile Nonhemolytic Transfusion Reaction (FNHTR)

The most commonly reported what

defined as a reaction that involves a increase in what

A
  1. The most commonly reported complications associated with transfusion.
  2. Defined as typical that the reaction involves an increase in body temperature of at least 33.8° F (1° C) either during or shortly after the transfusion.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
160
Q

Febrile Nonhemolytic Transfusion Reaction (FNHTR)

What is also considered FNHTR

A
  1. The occurrence of chills or rigor, even in the absence of fever, also is considered a FNHTR.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
161
Q

Febrile Nonhemolytic Transfusion Reaction (FNHTR)

Reactions occurs most frequently among

A
  1. Reaction occurs most frequently among people who have been multiply transfused or previously pregnant.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
162
Q

Febrile Nonhemolytic Transfusion Reaction (FNHTR)

Recurrences are common after

the reaction is generally what

A

Recurrences are common after an initial reaction is reported. The reaction, however, is generally mild and not considered to be life-threatening.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
163
Q

Febrile Nonhemolytic Transfusion Reaction (FNHTR)

is what type of reaction

A

FNHTR is a leukocyte-mediated reaction. Two known mechanisms exist:

164
Q

Febrile Nonhemolytic Transfusion Reaction (FNHTR)

Mechanism that involves the recipient being blank to HLA

A

The recipient has been alloimmumized to HLA because of exposure to foreign WBCs during pregnancy, transfusion, or transplant. The recipient’s HLA antibody attacks the transfused leukocytes that possess the concurrent antigen.

165
Q

Febrile Nonhemolytic Transfusion Reaction (FNHTR)

Mechanism that involves blank substances being release from what

A

 Cytokine substances are released from leukocytes during blood product storage. The cytokines are passively transfused to the recipient and initiate an inflammatory response.

166
Q

Febrile Nonhemolytic Transfusion Reaction (FNHTR)

The release of what causes fever

A

The release of pyrons in both mechanisms cause fever

167
Q

Febrile Nonhemolytic Transfusion Reaction (FNHTR)

The onset of symptoms of FNHTR occurs up to or during

definitive symptoms

A
  1. The onset of symptoms of FNHTR occurs during or up to 4 hours after transfusion. The definitive symptoms are fever >100.4° F (38° C) oral or equivalent with a change of >33.8° F (1° C) from pretransfusion value or occurrence of chills/rigors even in the absence of fever.
168
Q

Febrile Nonhemolytic Transfusion Reaction (FNHTR)

Secondary symptoms of FNHTR

A
  1. Other symptoms that may be present include respiratory distress (wheezing, coughing, dyspnea), hypertension or hypotension, headache, or vomiting.
169
Q

Febrile Nonhemolytic Transfusion Reaction (FNHTR)

follow up testing is determined by

  1. If symptoms of fever, chills, or rigor appear during transfusion, then
A

Because varying definitions of FNHTR exist, the criteria for diagnosis and follow-up testing are determined by each facility.

  1. If symptoms of fever, chills, or rigor appear during transfusion, the transfusion should be immediately discontinued. An antipyretic (i.e., acetaminophen) can be administered to reduce fever and alleviate patient discomfort.
170
Q

Febrile Nonhemolytic Transfusion Reaction (FNHTR)

An antipyretic can

A

An antipyretic (i.e., acetaminophen) can be administered to reduce fever and alleviate patient discomfort

171
Q

Febrile Nonhemolytic Transfusion Reaction (FNHTR)

  1. In certain circumstances, when it is likely that the fever is due to a FNHTR and not one of the life-threatening reactions, the reaction can be what
A

The transfusion may be restarted at a slower pace so long as the transfusion is completed within the required 4-hour timeframe. More frequent monitoring of the patient’s vital signs is often performed in these situations.

172
Q

Febrile Nonhemolytic Transfusion Reaction (FNHTR)

An effective method of prevention is

A
  1. An effective method of prevention is prestorage removal of leukocytes from blood products, which reduces the likelihood of the formation of antigen–antibody complexes as well as the release of cytokine substances.
173
Q

Febrile Nonhemolytic Transfusion Reaction (FNHTR)

Patients who are known to be susceptible to FNHTR are sometimes given an

A

Antipyretic prior to subsequent transfusions.

174
Q

Allergic Transfusion Reaction

Occurs in how much of the population

Are frequently encountered during

A
  1. Occur in 1–5% of the transfused population.
  2. Are frequently encountered during the transfusion of plasma products and can be identified in combination with febrile transfusion reactions.
175
Q

Allergic Transfusion Reaction

Typically are what within a few minutes

are caused by blank allergens

A

Typically are mild and occur within a few minutes of exposure to the allergen in the transfused product.
Are caused by protein-based allergens that react with preformed plasma antibodies

176
Q

Allergic Transfusion Reaction

Symptoms

blank is required to confirm the reaction

A

Symptoms are mucocutaneous and initially present as urticaria. A morbilliform or measles-like rash can occur with or without pruritus. Flushing of the skin and localized edema can occur, particularly on the lips, tongue, uvula, and periorbital area around the eyes. At least two symptoms must be observed in order for the allergic reaction to be confirmed.

177
Q

Allergic Transfusion Reaction

When symptoms appear what should be done
A
  1. When symptoms appear, the transfusion should be stopped immediately and intravenous access should be maintained
178
Q

Allergic Transfusion Reaction

what is given to reduce symptoms

A

An antihistamine such as diphenhydramine can be given orally or intramuscularly to reduce the symptoms and recipient discomfort.

179
Q

Allergic Transfusion Reaction

The transfusion can be resumed once

they are not completely what

A

The transfusion can be resumed once the symptoms resolve and if the reaction was mild.
Are not completely preventable.

180
Q

Anaphylactic/Anaphylactoid Transfusion Reaction

Are what rare allergic responses to blank?

A

Are rare allergic responses to plasma-containing blood products

181
Q

Anaphylactic/Anaphylactoid Transfusion Reaction

are what type of reaction and occur within

A

Nonhemolytic, type I hypersensitivity reactions that occur within minutes of exposure, typically after the infusion of a few milliliters of blood.

182
Q

Anaphylactic/Anaphylactoid Transfusion Reaction

are caused by a reaction between what and what

A

Protein allergen in the transfused product + corresponding antibody

183
Q

Anaphylactic/Anaphylactoid Transfusion Reaction

Anaphylactoid.

A

When reactions to plasma proteins result in the production of non-IgE class antibodies with non-IgE-mediated release of mast cell mediators

184
Q

Anaphylactic/Anaphylactoid Transfusion Reaction

Have the potential to occur in what antibody deficiency

A

IgA-deficient individuals when they have made antibodies to IgA after exposure to IgA through a previous transfusion or pregnancy.

185
Q

Anaphylactic/Anaphylactoid Transfusion Reaction

What distinguishes this conditions

A

The absence of fever is a key feature that distinguishes these reactions from others that have similar clinical presentations.

186
Q

Anaphylactic/Anaphylactoid Transfusion Reaction

Observable symptoms include

A

Severe respiratory problems, hypotension, mucocutaneous symptoms

Respiratory symptoms may be laryngeal. Pulmonary symptoms may be present.

187
Q

Anaphylactic/Anaphylactoid Transfusion Reaction

Confirmation must include
A
  1. Confirmation must include the rule-out of other environmental, drug, or dietary allergenic sources.
188
Q

Anaphylactic/Anaphylactoid Transfusion Reaction

  1. If reaction is suspected, then the

Transfusions are never what even if symptoms are resolved

A
  1. If reaction is suspected, the transfusion must be stopped immediately. The transfusion is never resumed even if immediate symptoms are resolved.
189
Q

Anaphylactic/Anaphylactoid Transfusion Reaction

Immediate medical intervention usually requires monitoring.

What should be kept open?

What is done to maintain respiratory function?

A

Immediate medical intervention usually requires monitoring the airway, blood volume, and blood pressure. The intravenous line should be kept open so that epinephrine and steroids, such as prednisone, can be administered. Oxygen therapy is given to maintain respiratory function. Intubation of the patient may be necessary.

190
Q

Anaphylactic/Anaphylactoid Transfusion Reaction

Prevention is based on

A

Prevention is based on previous history of either a suspected or confirmed severe reaction to a plasma-containing blood product.

191
Q

Transfusion Related Acute Lung Injury (TRALI)

Reported incidences range from as many as

is the leading cause of

A

Reported incidences range from as many as 1 in 1,300 transfusions to as few as 1 in 100,000.

The leading cause of transfusion-associated fatalities
192
Q

Transfusion Related Acute Lung Injury (TRALI)

Associated most often with what from female donors
A

Plasma-rich products from female donors, who are more likely to make alloantibodies because of exposure through pregnancies.

193
Q

Transfusion Related Acute Lung Injury (TRALI)

An acute adverse reaction that occurs within

Characterized by the onset of

A

6 hours of transfusion

Of acute hypoxemia in the absence of cardiac involvement.

194
Q

Transfusion Related Acute Lung Injury (TRALI)

it is generally agreed that blank are involves

The ultimate result of damage is where and results in

A

Neutrophils are involved, with the ultimate result of damage to the pulmonary capillaries and subsequent pulmonary edema.

195
Q

Transfusion Related Acute Lung Injury (TRALI)

is exclusively to the

A

pulmonary microvasculature

196
Q

Transfusion Related Acute Lung Injury (TRALI)

First step of TRALI

A

a preexisting condition causes the neutrophils to congregate in the lining of the lungs

197
Q

Transfusion Related Acute Lung Injury (TRALI)

Second step of TRALI

A

an immune or nonimmune process results in the onset of symptoms.

198
Q

Transfusion Related Acute Lung Injury (TRALI)

The diagnosis is complicated by other risk factors for

A

acute lung injury (ALI).

199
Q
A
200
Q

The Clinical workup for diagnosis should include a

A

CBC= show a decrease in circulating neutrophils

Visual inspection for hemolysis

DAT

201
Q
  1. When symptoms of TRALI are evident, the transfusion must be
A

must be stopped immediately. The bags of all units transfused within the last 6 hours should be returned to the laboratory and the unit that was the last to be transfused should be identified.

202
Q
  1. Because, in most cases, the culprit of TRALI arises from donor antibodies in a blood component

The patient does not have to

A

the patient does not have to go through any workup to prevent future reactions. Subsequent transfusions from a different donor are typically acceptable.

203
Q

E. Transfusion Related Acute Lung Injury (TRALI)

blood collection facilities have implemented the practice of selecting plasma from predominantly

A

male donors for transfusion because these collections are less likely to contain antibodies to neutrophils, which have often been implicated in cases of TRALI.

204
Q

E. Transfusion Related Acute Lung Injury (TRALI)

Plasma from female donors may be diverted to

A
  1. other purposes, such as further manufacturing into products like albumin and intravenous immune globulin (IVIG).
205
Q

F. Transfusion-Associated Circulatory Overload (TACO)

is a rarely reported what

A
  1. A rarely reported adverse reaction; it is believed that actual incidence is much higher because the reaction is underreported.
206
Q

A. Transfusion-Associated Circulatory Overload (TACO)

what is the most common cause

A

Rapid rate of infusion of blood products

207
Q
  1. To definitively diagnose, at least three of the following symptoms must occur within 6 hours of transfusion
A

-Acute respiratory distress; for example, dyspnea, orthopnea (difficulty breathing except when sitting upright), cough
-Evidence of positive fluid balance
-Elevated brain natriuretic peptide (BNP)
-X-ray evidence of pulmonary edema
-Evidence of left heart failure
-Elevated central venous pressure (CVP)

208
Q

F. Transfusion-Associated Circulatory Overload (TACO)

The clinical workup for suspected cases typically includes

A

electrocardiogram, pulmonary function tests, chest x-ray, monitoring of central venous pressure, and vital signs.

209
Q

F. Transfusion-Associated Circulatory Overload (TACO)

is often confused with what

how do you differentiate

A
  1. TRALI is often confused with TACO. Testing for brain natriuretic peptide (BNP) levels has been suggested as a noninvasive way to differentiate TACO and TRALI because BNP is elevated in TACO.
210
Q

F. Transfusion-Associated Circulatory Overload (TACO)

  1. If TACO is suspected then
A

the transfusion should either be stopped immediately or the rate of transfusion significantly slowed if the transfusion is vital.

211
Q

F. Transfusion-Associated Circulatory Overload (TACO)

Patients may be placed in an upright position to help with

supportive treatment includes what

A

respiratory distress and supportive treatment often includes oxygen therapy.

212
Q

F. Transfusion-Associated Circulatory Overload (TACO)

Diuretics may be given what to increase urinary output and reduce blood volume

A

??

213
Q

F. Transfusion-Associated Circulatory Overload (TACO)

  1. If severe symptoms persist then
A
  1. If severe symptoms persist, therapeutic phlebotomy can be used to rapidly reduce blood volume.
214
Q

F. Transfusion-Associated Circulatory Overload (TACO)

TACO is prevented by identifying patients in

A

high-risk groups and taking appropriate measures to limit the rapid expansion of blood volume during transfusion

215
Q

G. Transfusion-Associated Dyspnea (TAD)

A
  1. Term that describes transfusion reactions when a patient experienced respiratory distress but when TRALI, TACO, and other causes have been ruled out.
216
Q

Hypotensive Transfusion Reactions

Definition

A
  1. Identified as a drop in blood pressure (systolic or diastolic) of >30 mm Hg that occurs during or within 1 hour after the transfusion.
217
Q

Hypotensive Transfusion Reactions

The diagnosis is often difficult because

A

many adverse reactions to transfusion include symptoms of hypotension.

218
Q

Hypotensive Transfusion Reactions

what is the most common blood component implicated

A
  1. Platelet units are the most common blood component implicated
219
Q

Hypotensive Transfusion Reactions

hypotensive reactions are related to

A
  1. Hypotensive reactions are related to bradykinin function and metabolism. Bradykinin is a peptide, produced naturally in the body by the kinin–kallikrein system of blood proteins. Bradykinin causes vasodilation and subsequent lowering of blood pressure.
220
Q

Hypotensive Transfusion Reactions

Bradykinin

A

Bradykinin is a peptide, produced naturally in the body by the kinin–kallikrein system of blood proteins. Bradykinin causes vasodilation and subsequent lowering of blood pressure.

221
Q

Hypotensive Transfusion Reactions

  1. In order to diagnose a hypotensive transfusion reaction what is essential
A

that other adverse reactions characterized by symptoms of hypotension are excluded.

222
Q
  1. When hypotensive transfusion reactions are suspected, what must be discontinued

what is the medicine for treatment

A

the transfusion must be discontinued immediately. Treatment, including vasopressors to increase blood pressure, can be administered to offset symptoms.

223
Q

Hypotensive Transfusion Reactions

Reaction can be prevented by

A

discontinuing ACE inhibitor treatment for a period of time before blood transfusion is administered.

The elimination of bedside leukoreduction filters is also recommended.

224
Q

Transfusion-Associated Graft versus Host Disease (TA-GVHD)

mortality rate is

death occurs when

A

A rare complication of transfusion, but the mortality rate is approximately 90%.

Death occurs rapidly, within 1–3 weeks of onset.

225
Q

Transfusion-Associated Graft versus Host Disease (TA-GVHD)

Caused by

A

Caused by donor T-cell lymphocytes from transfused blood products that are able to recognize the host (or recipient) cells as a result of differences in human leukocyte antigens (HLAs). The donor T-cell lymphocytes attack the host’s tissues that carry the different HLA.

226
Q

Transfusion-Associated Graft versus Host Disease (TA-GVHD)

blank states interfere with the recipients ability to eliminate the donor lymphocytes predispose transfusion recipients to developing TA-GVHD.

A

Certain immunodeficient states that interfere with the recipient’s ability to eliminate the donor lymphocytes predispose transfusion recipients to developing TA-GVHD.

227
Q

Transfusion-Associated Graft versus Host Disease (TA-GVHD)

symptoms

symptoms occur when

A

Symptoms typically occur within a few days to approximately 6 weeks after transfusion.

Symptoms include fever, body rash, enlarged liver, and diarrhea

228
Q

Transfusion-Associated Graft versus Host Disease (TA-GVHD)

  1. The diagnosis may not always be immediately evident because
A

of its rarity, the delay from transfusion to onset of symptoms, and the general symptoms of rash and diarrhea are not necessarily specific to TA-GVHD.

229
Q

Transfusion-Associated Graft versus Host Disease (TA-GVHD)

Gamma irradiation is effective in

There is no

A

Gamma irradiation is effective in preventing and acts by inactivation of donor lymphocytes, inhibiting their ability to proliferate in the host.

standard therapy

230
Q

Hemosiderosis is known as

A

iron overload

231
Q

Hemosiderosis

Is an adverse response to

A

An adverse response to multiple (usually > 100) red blood cell transfusions.

232
Q

Hemosiderosis

A concern in what type of transfused patient

A

chronically transfused patients such as sickle cell disease or thalassemia patients and less commonly occurring patients are hereditary hemolytic anemias and hemoglobinopathies are also at risk.

233
Q

Hemosiderosis

overall incidence is

symptoms include

Laboratory findings of

A
  • Overall incidence is low.
  • The physical symptoms include weakness and fatigue.
  • Laboratory findings of jaundice, anemia, and cardiac arrhythmia are often present.
234
Q

Hemosiderosis

If left untreated it can lead to

A

liver and/or heart failure.

235
Q

Hemosiderosis

Prevention is best achieved by

Iron toxicity can be prevented by

A

Iron toxicity can be prevented, delayed, or treated with iron chelation therapy.

Prevention is best achieved by limiting transfusion of red blood cell products.

236
Q

Post-Transfusion Purpura (PTP)

majority of cases occurs in

A

females over the age of 60

236
Q

Post-Transfusion Purpura (PTP)

Presents with life threating

A

thrombocytopenia.

237
Q

Post-Transfusion Purpura (PTP)

main cause of death

A

Cerebral hemorrhage

238
Q

Post-Transfusion Purpura (PTP)

what has decreased the incidence over the past several years

A

Transfusion of leukoreduced blood products has decreased the incidence over the past several years.

239
Q

Post-Transfusion Purpura (PTP)

the majority of cases involve

A

antigen-negative patients who develop alloantibodies after exposure to platelet antigens through pregnancy or transfusion.

240
Q

Post-Transfusion Purpura (PTP)

what is the classic presentation

and the disease tends to

A

Wet purpura

resolve on its own.

241
Q

Post-Transfusion Purpura (PTP)

Treatment methods for managing PTP include

A

intravenous immune globulin, plasmapheresis, high-dose steroids, and splenectomy. Intravenous immune globulin is currently considered the treatment of choice.

242
Q

Post-Transfusion Purpura (PTP)

treatment method of choice

A

Intravenous immune globulin is currently considered the treatment of choice.

243
Q

K. Post-Transfusion Purpura (PTP)

Platelet transfusions are not

A

recommended for treatment of PTP because the transfused platelets will be destroyed.

244
Q

K. Post-Transfusion Purpura (PTP)

Although recurrence of PTP is rare even for those patients with a confirmed history, what is recommended still

A

antigen-negative platelets are recommended for future transfusions

245
Q

Reactions Associated with Massive Transfusion

The following transfusion reactions are most commonly associated with rapid transfusion of large amounts of blood products
A

-Citrate toxicity
-Hypothermia
-Dilutional coagulopathy

246
Q

Nonimmune hemolysis

Several conditions, both physical and chemical in origin, can cause
A

red blood cells to hemolyze prior to transfusion.

247
Q

Nonimmune hemolysis

symptoms

A
248
Q

Nonimmune hemolysis

symptoms may be subtle but include what

Absence of blank is common

A
  1. Symptoms may be subtle but typically include chills, hypotension, hemoglobinuria, and shortness of breath.
  2. Absence of fever is a common finding in both physical and chemical types of hemolysis.
249
Q

Nonimmune hemolysis

The differential diagnosis requires
A

the initial rule-out of immune hemolytic transfusion reaction (either immediate or delayed) or intrinsic defects in either the donor or recipient red blood cell membrane.

250
Q

Nonimmune hemolysis

When suspected, the transfusion should be

A

be stopped and the intravenous line kept open. Cardiac and respiratory function should be monitored

251
Q

Nonimmune hemolysis

Is best prevented through

A

Is best prevented through adherence to written protocols and standards.

252
Q

Initial Laboratory Investigation of Suspected Transfusion Reaction

Because many types of transfusion reactions demonstrate similar symptoms it is critical that
A

it is critical that a complete follow-up and investigation be performed on every reported reaction.

253
Q

Initial Laboratory Investigation of Suspected Transfusion Reaction

When investigating a transfusion reaction both what are critical
A

both the clinical evaluation and the laboratory work-up are critical to correctly diagnosing the etiology of the reaction

254
Q

Initial Laboratory Investigation of Suspected Transfusion Reaction

Depending on the symptoms and the patient history, the laboratory may request that
A

any remaining blood component, along with the infusion tubing, be forwarded to the laboratory along with a post-transfusion blood sample for investigation.

255
Q

Initial Laboratory Investigation of Suspected Transfusion Reaction

Intial Laboratory investigation includes

A

Initial laboratory investigation includes a clerical check for errors on the pretransfusion specimen label, initial laboratory requisition, other paperwork, pretransfusion testing results, component tags and labels, and the post-transfusion specimen label.

256
Q

Initial Laboratory Investigation of Suspected Transfusion Reaction

The pre- and post-transfusion samples are visually inspected for

a DAT is preformed on what sample

A

for signs of hemolysis, although low levels in free hemoglobin may not be visible to the naked eye, and a direct antiglobulin test (DAT) is performed on the post-transfusion sample.

257
Q

The period beginning as early as the 20th week of gestation or as late as the 28th week of pregnancy and ending 28 days after birth.

A

Perinatal

258
Q

Newborn from birth to 4 weeks of age.

A

Neonate

259
Q

For transfusion purposes, neonates are babies who are ____ months old or less and infants are babies over ____ months of age.

A

4 months
4 months

260
Q

Number of pregnancies experienced by a woman regardless of whether they resulted in a birth or not.

A

Gravida

261
Q

Delivery of a live infant.

A

Para

262
Q

The shortened lifespan of fetal or neonatal red blood cells caused by the action of maternal antibodies attaching to corresponding antigens on the baby’s red blood cells (RBCs).

A

Hemolytic Disease of the Fetus and Newborn (HDFN)

263
Q

Conditions that Cause Red Blood Cell Hemolysis in the Fetus or Newborn
1. Genetic red blood cell membrane defects, enzyme deficiencies, or hemoglobinopathies:

A

 Glucose-6-phosphate dehydrogenase deficiency
 Pyruvate kinase deficiency
 Thalassemia
 Hereditary spherocytosis
 Hereditary elliptocytosis
 Disorders of hemoglobin synthesis

264
Q

Conditions that Cause Red Blood Cell Hemolysis in the Fetus or Newborn:

Acquired defects of the red blood cells secondary to infection:

A

 Toxoplasmosis, rubella, cytomegalovirus, herpes simplex (TORCH)
 Parvovirus B19
 Syphilis

265
Q

Stages of Pathogenesis of HDFN

A
  1. Step 1: Exposure of the mother to fetal RBC antigens with subsequent production of blood group antibodies (anti A,B is an exception that does not require previous exposure to RBC antigens).
  2. Step 2: Placental transfer of the maternal antibodies to the fetus with attachment to fetal RBC antigens.
  3. Step 3: Subsequent immune destruction of the antibody-coated fetal red blood cells.
  4. Step 4: Clinical manifestations resulting from the destruction of these marked red blood cells
266
Q

Conditions Necessary for Maternal Antibody Formation in Hemolytic Disease of the Fetus and Newborn

A
  1. The mother must lack the antigen present on the fetal RBCs
  2. The fetal antigen must be well developed in utero
  3. The mother is exposed to the fetal antigen
  4. The mother produces an IgG antibody to the antigen, capable of crossing the placenta
267
Q

Three sensitization-related aspects associated with laboratory testing of a mother suspected of having HDFN include:

A

-Antigens
-Immunoglobulin class
-Influence of ABO groups

268
Q

Transfusion-Transmitted Infections
Hepatitis A

What type of virus is it, and the family

A
  1. Small, nonenveloped RNA virus in the Picornaviridae family
269
Q

Transfusion-Transmitted Infections
Hepatitis A

How is it transmitted?

Is it the most common hepatitis virus

A
  • Transmitted when unsanitary conditions result in contaminated food or water, which is then ingested.
    The most common of all the hepatitis viruses.
    Ttransmitted mainly through the fecal–oral route
270
Q

Transfusion-Transmitted Infections
Hepatitis A

Incubation period and symptoms

A

The incubation period is about 4 weeks.
Symptoms include fatigue, fever, jaundice, and vomiting

271
Q

Transfusion-Transmitted Infections
Hepatitis A

The period of active infection usually lasts less than blank , and there is no know blank

A

The period of active infection usually lasts less than blank, and there are no known Chronic carrier states.

272
Q

Transfusion-Transmitted Infections
Hepatitis A

Most common fatalities cause

Transmissible through

A

Rare fatalities have been documented, mainly in older adults or those with preexisting liver disease.
Transmissible through blood transfusion, although rare.

273
Q

Transfusion-Transmitted Infections
Hepatitis B

Type of virus and family

A

An enveloped DNA virus in the Hepadnaviridae family

274
Q

Transfusion-Transmitted Infections
Hepatitis B

Prevalence

transmission

A

Prevalence in the United States has decreased during the last couple of decades as a result of available vaccination.

Can be transmitted sexually, parenterally, and vertically.

275
Q

Transfusion-Transmitted Infections
Hepatitis B

Percutaneous transmission can occur by
A

Breaking the skin with contaminated sharp objects such as surgical instruments and phlebotomy needles.

276
Q

Transfusion-Transmitted Infections
Hepatitis B

how long can the virus survive in dried blood

A

1 week

277
Q

Transfusion-Transmitted Infections
Hepatitis B

symptoms

A

flu-like symptoms, jaundice, and elevated liver enzymes and present after a 2- to 6-month incubation period.

278
Q

Transfusion-Transmitted Infections
Hepatitis B

A small percentage of long-term carriers of HBV will progress to
A

Chronic disease

279
Q

Transfusion-Transmitted Infections
Hepatitis B

Complications of chronic infection include

A

Cirrhosis of the liver and hepatocellular carcinoma, which together cause most of the fatalities associated with HBV.

280
Q

Transfusion-Transmitted Infections
Hepatitis B

  1. HBV is a blank virus and is transmitted through blank
A

HBV is a plasma-borne virus that is easily transmitted through all blood components and most products. The risk of transmission is highest when plasma is pooled for the manufacture of plasma products and derivatives.

281
Q

Transfusion-Transmitted Infections
Hepatitis B

The current risk in the US of HBV infection from a transfusion is

A

1:220,000

282
Q

Transfusion-Transmitted Infections
Hepatitis C

Type of virus and family

A

Small, enveloped RNA virus in the Flaviviridae family

283
Q

Transfusion-Transmitted Infections
Hepatitis C

Prevalence

A

Prevalent in the United States, with more than 20,000 new cases each year and 3 million chronic carriers.

284
Q

Transfusion-Transmitted Infections
Hepatitis C

Transmission

A

Intravenous drug use and sharing of needles between partners are the most common sources of transmission. Sexual and placental transmissions are possible; however, they are uncommon.

285
Q

Transfusion-Transmitted Infections
Hepatitis C

Most acute cases are

A

asymptomatic

286
Q

Transfusion-Transmitted Infections
Hepatitis C

symptoms

A

Symptoms include jaundice and elevated liver enzymes that indicate changes in liver function.

287
Q

Transfusion-Transmitted Infections
Hepatitis C

% of chronic carriers

A

Approximately 80% of persons infected with HCV become chronic carriers

288
Q

Transfusion-Transmitted Infections
Hepatitis C

Long term risk

A

The long-term risk of chronic carrier status includes cirrhosis of the liver and hepatocellular carcinoma.

289
Q

Transfusion-Transmitted Infections
Hepatitis D

type of virus and family

A

small RNA virus( delta virus)

family: not classified because dependent on HBV

290
Q

Transfusion-Transmitted Infections
Hepatitis D

Transmission

A

Transmitted mainly through parenteral and sexual routes, but only in the presence of HBV.

291
Q

Transfusion-Transmitted Infections
Hepatitis D

Coinfection

A

People with hepatitis B and hepatitis D co-infection experience a more severe, acute illness than those infected with hepatitis B alone.

292
Q

Transfusion-Transmitted Infections
Hepatitis D

Assays

A

Assays to detect antibodies to HDV are available; however, blood donor screening for HDV is not recommended because the elimination of hepatitis B–positive donors eliminates the risk of HDV transmission.

293
Q

Transfusion-Transmitted Infections
Hepatitis E

Type of virus and family

A

Nonenveloped RNA virus in the Hepeviridae family

294
Q

Transfusion-Transmitted Infections
Hepatitis E

Transmission

A

Transmitted mainly through the fecal–oral route. It is not known to be sexually transmitted

295
Q

Transfusion-Transmitted Infections
Hepatitis E

Illness usually involves a

A

The illness usually involves a mild form of hepatitis, and few fatalities have been reported from complications of liver disease

296
Q

Transfusion-Transmitted Infections
Hepatitis E

Most cases are

A

Most cases are acute and do not proceed to a chronic illness.

297
Q

Transfusion-Transmitted Infections
Hepatitis E

area of infection from transfusion

Serologic testing

A

Rare transfusion transmission of HEV from infected donors has been reported in countries outside of the United States.
Serologic tests for HEV are available; however, blood donor screening for HEV is not recommended because transmission in the United States is unsubstantiated

298
Q

Transfusion-Transmitted Infections
Hepatitis G

Also called what

Family and type of virus

A

-Also called GB virus

-Enveloped RNA virus in the Flaviviridae family.

299
Q

Transfusion-Transmitted Infections
Hepatitis G

Transmission

A

Although HGV is transmitted through blood transfusion, the virus does not appear to cause disease in humans.

300
Q

Transfusion-Transmitted Infections
Hepatitis G

Does not cause

A

hepatitis-like illness

301
Q

Transfusion-Transmitted Infections
Hepatitis G

Assays

A

Although assays for the identification of HGV are available, blood donor screening for HGV is not recommended because of the lack of an associated disease state.

302
Q

Transfusion-Transmitted Infections
Retroviruses:

Human Immunodeficiency Virus (HIV) I and II

Type of virus and family

A

Enveloped virus in the Retroviridae family. HIV is composed of an outer envelope of proteins around an inner core of RNA and reverse transcriptase enzyme.

303
Q

Transfusion-Transmitted Infections
Retroviruses:

Human Immunodeficiency Virus (HIV) I and II

The subtypes of HIV-I and II share up to

A

50% of their genetic sequence; this creates the potential for cross-reactivity during testing.

304
Q

Transfusion-Transmitted Infections
Retroviruses:

Human Immunodeficiency Virus (HIV) I and II

Prevalence

A

HIV-I is prevalent worldwide, and HIV-II is endemic in western Africa.

305
Q

Transfusion-Transmitted Infections
Retroviruses:

Human Immunodeficiency Virus (HIV) I and II

HIV is mainly concentrated in
A

Plasma

306
Q

Transfusion-Transmitted Infections
Retroviruses:

Human Immunodeficiency Virus (HIV) I and II
  1. Both HIV-I and II are the causative agents of
A

Acquired immunodeficiency syndrome (AIDS).

307
Q

Transfusion-Transmitted Infections
Retroviruses:

Human Immunodeficiency Virus (HIV) I and II

HIV is transmitted
A

Parenterally, sexually, vertically, and through breast milk.

308
Q

Transfusion-Transmitted Infections
Retroviruses:

Human Immunodeficiency Virus (HIV) I and II
  1. Approximately 40% of people that are infected with HIV exhibit
A

Flu-like symptoms, with the remainder of infections being asymptomatic for 10 years or longer.

309
Q

Transfusion-Transmitted Infections
Retroviruses:

Human Immunodeficiency Virus (HIV) I and II

The combined strategies of donor deferral, confidential self-exclusion, and transmissible disease testing have reduced blank.

A

The overall risk of transfusion-transmitted HIV I/II to 1:2,000,000.

310
Q

Transfusion-Transmitted Infections
Retroviruses:

Human T-Cell Lymphotrophic Virus (HTLV) I and II

Type of virus

A
  1. Delta retroviruses
311
Q

Transfusion-Transmitted Infections
Retroviruses:

Human T-Cell Lymphotrophic Virus (HTLV) I and II

A very small percentage of HTLV-infected people develop either
A

the rare adult T-cell leukemia/lymphoma (ATL) or a demyelinating neurologic disorder known as HTLV-associated myelopathy (HAM) or tropical spastic paraparesis.

311
Q

Transfusion-Transmitted Infections
Retroviruses:

Human T-Cell Lymphotrophic Virus (HTLV) I and II

Type one is endemic in

A

Certain parts of Japan, South America, the Caribbean, and Africa.

311
Q

Transfusion-Transmitted Infections
Retroviruses:

Human T-Cell Lymphotrophic Virus (HTLV) I and II

HTLV is transmissible through
A

blood transfusion and is capable of inducing active infection in a recipient.

311
Q

Transfusion-Transmitted Infections
Retroviruses:

Human T-Cell Lymphotrophic Virus (HTLV) I and II
  1. HTLV II makes up about blank % of cases in the US and what group of people are most likely to get it
A

50% and is particularly among drug abusers.

311
Q

Transfusion-Transmitted Infections
Retroviruses:

Human T-Cell Lymphotrophic Virus (HTLV) I and II

Modes of transmission

A

The modes of transmission are parenteral and sexual, and through breast milk.

311
Q

Transfusion-Transmitted Infections
Retroviruses:

Human T-Cell Lymphotrophic Virus (HTLV) I and II
  1. Active infection is usually
A

Asymptomatic and infection is life-long

312
Q

Transfusion-Transmitted Infections
Retroviruses:

Human T-Cell Lymphotrophic Virus (HTLV) I and II
  1. Refrigeration and storage of red blood cell products for more than 10 days results in blank
A

Degradation of the lymphocytes and a drop in viral load that subsequently reduces the likelihood of transmission.

313
Q

Transfusion-Transmitted Infections
Retroviruses:

Human T-Cell Lymphotrophic Virus (HTLV) I and II

Leukocyte reduction of red blood cell products is also recommended to

A

minimize the incidence of transfusion-transmitted HTLV

314
Q

Parvovirus B19

the only Known

A

pathogenic human parvovirus

315
Q

Parvovirus B19

type of virus and infects what therefore classified as

A

-Nonenveloped single DNA virus.
-Infects red blood cells and therefore is classified as an erythrovirus.

316
Q

-Parvovirus B19

Mainly transmitted through

A

the respiratory route by way of aerosols.

317
Q

Parvovirus B19

causes a common

A

Parvovirus causes a common childhood illness called erythema infectiosum or fifth disease.

318
Q

Parvovirus B19

Approximately 50% of adults have been exposed to
A

parvovirus with no complications.

319
Q

Parvovirus B19

Persons at risk for complications from parvovirus include
A

Immunocompromised patients, pregnant women, and people with reduced RBC lifespan such as in sickle cell disease or other hemoglobinopathies.

320
Q

Parvovirus B19

Parvovirus is transmitted mainly in
A

Plasma products and to a lesser extent, red blood cell products.

321
Q

Parvovirus B19

It is resistant mainly to

A

common methods of pathogen inactivation including both heat treatment and solvent detergent.

322
Q

Parvovirus B19

There is currently no screening protocol for

A

Parvovirus among blood donors.

323
Q

Epstein-Barr Virus (EVB)

Member of the

A

Herpesviridae family

324
Q

Epstein-Barr Virus (EVB)

Exposure rate

A

In the United States, approximately 95% of the adult population over age 40 has been exposed to EBV

325
Q

Epstein-Barr Virus (EVB)

Mainly acquired through

A

through contact with infected saliva aka kissing disease

326
Q

Epstein-Barr Virus (EVB)

Causative agent

A

infectious mononucleosis

327
Q

Epstein-Barr Virus (EVB)

can be asymptomati or can demonstrate Symptoms of

A

demonstrate symptoms of sore throat, enlarged lymph nodes, fever, lethargy, and malaise.

327
Q

Epstein-Barr Virus (EVB)

Whos at increased risk for complications from EBV infection and several lymphomas have a correlation with EBV infection.

A
  1. Immunocompromised people
328
Q

Epstein-Barr Virus (EVB)

Infects

A

B lymphocytes that can result in latent infection that lasts throughout life.

329
Q

Epstein-Barr Virus (EVB)

  1. A few cases of transfusion-transmitted of blank have been reported
A

EBV

330
Q

Epstein-Barr Virus (EVB)

there is no screening protocol for

A

EBV detection among blood donors

331
Q

Epstein-Barr Virus (EVB)

To prevent complications from transfusion-transmitted EBV, it is recommended that.
A

Seronegative individuals that are immunocompromised receive leukocyte-reduced blood products.

Some transfusion facilities will also test donors of products for immunocompromised seronegative recipients for EBV antibodies.

332
Q

Cytomegalovirus (CMV)

Type of virus and family

A

DNA virus that is a member of the Betaherpesvirinae subfamily.

333
Q

Cytomegalovirus (CMV)

Exposure rates for adults

A

adults in the United States rates range between 50% and 85%.

334
Q

Cytomegalovirus (CMV)

transmission

A

The mode of transmission is through direct contact of blood and body fluids with infected leukocytes.

335
Q

Cytomegalovirus (CMV)

Transmission is through

A

direct contact of blood and body fluids with infected leukocytes.

336
Q

Cytomegalovirus (CMV)

Typically causes a
A

Mild or asymptomatic illness in healthy individuals.

337
Q

Cytomegalovirus (CMV)

After initial infection, CMV can remain latent for
A

several years and become reactive later in life.

338
Q

Cytomegalovirus (CMV)

It can cause severe and potentially life-threatening complications in
A

high-risk groups

339
Q

Cytomegalovirus (CMV)

Individuals who are at risk for complications from CMV infection include those who are
A

immunosuppressed, including low birth weight neonates and cellular or solid organ transplant recipients.

340
Q
  1. CMV is detectable through immunological techniques including
A

ELISA, fluorescence assay, hemagglutination, and latex agglutination.

341
Q

CMV

  1. Although it is not possible to completely eliminate the incidence of transfusion-transmitted CMV blank reduction has significantly reduced the number of reported cases.
A

leukocyte reduction

342
Q

West Nile Virus (WNV)

A
343
Q

West Nile Virus (WNV)

Type of virus and family

A

Single-strand enveloped RNA virus of the Flaviviridae family.

344
Q

West Nile Virus (WNV)

Found primarily in
A

bird species but can also be found in other animals, including horses and cattle.

345
Q

West Nile Virus (WNV)

Transmitted to humans through

A

infected mosquitoes

346
Q

West Nile Virus (WNV)

Eighty percent of humans infected with WNV are
A

Asymptomatic.

347
Q

West Nile Virus (WNV)

  1. People with symptomatic infection, called blank develop what
A

WNV fever, develop flu-like symptoms that include fever, rash, headache, and vomiting.

348
Q

West Nile Virus (WNV)

Symptoms usually last from

A

usually last from 3 to 6 days and only supportive care is needed. Rare complications, in as few as 0.7% of WNV infections, include encephalitis and meningitis.

349
Q

West Nile Virus (WNV)

In people over age 50, there is an increased risk of
A

long-term neurological symptoms

350
Q

West Nile Virus (WNV)

Transmissible through
A

blood products

351
Q

West Nile Virus (WNV)

In 2003 what happened

A

a screening test was developed and added to blood donor testing.

352
Q

Human Herpes Virus 6 (HHV6)

Viral agent that causes

Common childhood illness that is transmitted by
A

roseola infantum or sixth disease.

transmitted mainly through the respiratory route.

353
Q

Human Herpes Virus 6 (HHV6)

Prevalent in the

not known to be transmissible through

A

The general population and most adults have had previous exposure to the virus.

*** Not known to be transmissible through blood transfusion.

354
Q

Human Herpes 8 HHV8

Associated with

Transmitted by

A

Kaposi’s sarcoma and not a common virus in the general population.

Transmitted parenterally and is present in blood, saliva, and semen.
355
Q

Human Herpes Virus 8 HHV8

% of blood donors in the United States are seropositive for HHV-8.

A

3-5%

356
Q

Human Herpes Virus 8 HHV8

 Transmission may be a concern in

A

immunosuppressed patients

357
Q

Human Herpes Virus 8 HHV8

Testing

A

 At the present time, testing for HHV-8 among blood donors is not recommended.

358
Q

SEN Virus

Family and type of virus

A

Nonenveloped DNA virus in the Circoviridae family.

359
Q

SEN Virus

There is a high prevalence of SEN-V among
A

Transfusion recipients and the virus is known to be transmitted through blood transfusion.

360
Q

SEN Virus

Since there is no known disease association, screening of blood donors for SEN-V is
A

Not recommended

361
Q

Torque Teno Virus (TTV)

Prevalence

A
  1. Found in the general population and has been identified in approximately 10% of blood donors in the United
362
Q

Torque Teno Virus (TTV)

Transmission and disease association

A
  1. Although it is known to be transmitted through blood and body fluids, no disease association for TTV has been established.
363
Q

Torque Teno Virus (TTV)

Screening of blood donors for TTV is
A

not currently recommended.

364
Q

Prions

Description of infection

A
  1. Refers to infectious self-regulating proteins that convert normal proteins into abnormal structures.
365
Q

Prions

Group of diseases is called

A

transmissible spongiform encephalitis (TSE), with different disease names being applied to different species of affected animals.

366
Q

Prions

Prion diseases typically affect the
A

brain and neurologic function when abnormal protein aggregates cause sponge-like lesions in brain tissue.

367
Q

Prions

Human diseases

A

 Creutzfeld-Jakob disease (CJD)
 Variant Creutzfeld-Jakob disease (vDJD)
 Kuru
 Gerstmann–Straussler–Scheinker syndrome (GSS)
 Fatal familial insomnia (FFI)

368
Q

Prions

Cattle disease

A

 Bovine spongiform encephalopathy (BSE; “mad cow disease”)

369
Q

Prions

sheep/goat diseases

A

Scrapie

370
Q

Prions
Greater kudu/nyala diseases

A

Exotic ungulate encephalopathy (EUE)

371
Q

Prions

Mink diseases

A

Transmissible mink encephalopathy (TME)

372
Q

Prions Cat diseases

A

Feline spongiform encephalopathy

373
Q

Prions: Diseases Associated with Creutzfeld-Jakob Disease (CJD)
1. Creutzfeldt-Jakob disease (CJD)

It can be transmitted through
A

Human growth hormone products from human pituitary glands (no longer allowed), intravenous immunoglobulin (IVIG), infected electrodes for EEGs, cannibalism, and some transplant materials.

374
Q

Prions: Diseases Associated with Creutzfeld-Jakob Disease (CJD)
1. Creutzfeldt-Jakob disease (CJD)

There is also a known hereditary component but is

A

which is rare, and sometimes the etiology remains unknown especially given the long incubation period.

375
Q

Prions: Diseases Associated with Creutzfeld-Jakob Disease (CJD)
1. Creutzfeldt-Jakob disease (CJD)

Incubation period

A

can last anywhere from 4 to 20 years and very few patients exhibit symptoms before age 50.

376
Q

Prions: Diseases Associated with Creutzfeld-Jakob Disease (CJD)
1. Creutzfeldt-Jakob disease (CJD)

Onset of symptoms

A

Is sudden and often includes rapidly progressing dementia, poor coordination, visual problems, and involuntary movements.

377
Q

Prions: Diseases Associated with Creutzfeld-Jakob Disease (CJD)
1. Creutzfeldt-Jakob disease (CJD)

All cases are eventually

A

fatal, with death usually occurring within 1 year of the onset of symptoms.

378
Q

Prions: Diseases Associated with Creutzfeld-Jakob Disease (CJD)
1. Creutzfeldt-Jakob disease (CJD)

 There have been no confirmed cases of

A

Transmission of CJD through blood products. Blood donor screening for CJD is not currently recommended.

379
Q

Prions: Diseases Associated with Creutzfeld-Jakob Disease (CJD)
Variant Creutzfeldt-Jakob disease (vCJD)

type of disease and different from what

A

 Fatal neurological disease.
 Different from CJD in terms of disease progression

380
Q

Prions: Diseases Associated with Creutzfeld-Jakob Disease (CJD)
Variant Creutzfeldt-Jakob disease (vCJD)

age of infection

A

 Patients with vCJD are usually younger than 40 years old, whereas classic CJD is primarily a disease of older adults.

381
Q

Prions: Diseases Associated with Creutzfeld-Jakob Disease (CJD)
Variant Creutzfeldt-Jakob disease (vCJD)

The outbreak of the new disease has been linked to

A

has been linked to the eating of infected beef after a change in the disinfectant used to clean slaughter houses

382
Q

Prions: Diseases Associated with Creutzfeld-Jakob Disease (CJD)
Variant Creutzfeldt-Jakob disease (vCJD)

 In contrast to classic CJD, vCJD is transmissible through

A

blood transfusion

383
Q

Prions: Diseases Associated with Creutzfeld-Jakob Disease (CJD)
Variant Creutzfeldt-Jakob disease (vCJD)

Because the disease is eventually blank
A

Fatal, several strategies have been implemented in the United States and other countries to reduce the risk of transmission of vCJD through infected blood products.

384
Q

Bacterial Contamination of Blood Products

Bacterial Contamination of Donor Blood 

Transmission

A

a. A rare occurrence.
b. Reports of transfusion-transmitted bacteremia indicate that most blood component contamination occurs during venipuncture at time of collection or during the manufacture and handling of blood components.

385
Q

Bacterial Contamination of Blood Products

Bacterial Contamination of Donor Blood

The most frequently identified causes of contamination are

A

poor disinfection of the venipuncture site or improper handling of an open product, for example, if the bag or vial has a crack or a broken seal.

386
Q

Bacterial Contamination of Blood Products

Bacterial Contamination of Donor Blood

Transfusion of bacterially contaminated blood components causes
A

sepsis in the recipient.

386
Q

Bacterial Contamination of Blood Products

Bacterial Contamination of Donor Blood

Regardless of the cause, bacterial contamination of blood products is associated with a

A

high incidence of morbidity and mortality and therefore poses a serious health threat.

387
Q

Bacterial Contamination of Blood Products

Bacterial Contamination of Donor Blood

blank are most frequently implicated in transfusion-transmitted bacteremia.

A

Platelet products

387
Q

Bacterial Contamination of Blood Products

Bacterial Contamination of Donor blood 

g. While donors may have no symptoms or only minor symptoms and a low bacteremia. patients can have

A

severe transfusion reactions (sometimes fatal) to the bacteria and endotoxin present within blood products at the time of transfusion

388
Q

Bacterial Contamination of Blood Products

Bacterial Contamination of Donor blood 

Two bacterial diseases with a known history of being transmitted through blood products include
A

syphilis and Lyme disease.

389
Q

Associated Bacterial Diseases

Syphilis

Caused by and spread through

A

i. Caused by the spirochete Treponemia pallidum.
ii. Most commonly spread through sexual contact

390
Q

Associated Bacterial Diseases

Syphilis 

Transfusion transmitted is

Incubation period

A

iii. Transfusion-transmitted syphilis is rare.
iv. The incubation period for infected persons is from 4 weeks to 5 months.

391
Q

Associated Bacterial Diseases

Syphilis

Treat with

donor with syphilis cant

A

v. Active infection is readily treated with antibiotics( penicillin)
vi. Donors with a positive test for syphilis are deferred from donating blood for 12 months.

392
Q

Associated Bacterial Diseases

Lyme disease

Caused by

Spread by a

A

i. Caused by the spirochete Borrelia burgdorferi.
ii. Bacterial illness that is spread by a tick bite.

393
Q

Associated Bacterial Diseases

Lyme disease 

prevalence in the US

A

iii. In the United States, no cases of transfusion-transmitted Lyme disease have been reported, but the disease is present in the general population and in the donor population.

394
Q

Lyme disease

Blood donors who have a history of Lyme disease can donate if they have

A

no visible symptoms, have completed a full course of antibiotics, and have been cleared to donate by a physician.

395
Q

Lyme disease

v. Screening of blood donors for Lyme disease as part of the

A

the transmissible disease test process is not currently recommended.

396
Q

Parasitic infection

a. Babesiosis

caused by

A

Babesia microti.

397
Q

Parasitic Infections

Babesiosis

transmitted to

A

ii. Transmitted to humans through tick bites, specifically from the Ixodes tick, which is also called the deer tick.

398
Q

Parasitic Infections

Babesiosis- Common in the United States, particularly
A

The Northeast during warm-weather seasons when ticks are likely to be abundant.

399
Q

Babesiosis

Although many cases are asymptomatic,

A

A symptomatic person will experience fever, chills, lethargy, and, in some cases, hemolytic anemia. In rare cases, the disease may be fatal.